HQL 79

Key Product Details

Product Description

HQL 79 is an orally active and specific inhibitor of human hematopoietic prostaglandin D synthase (H-PGDS) (IC₅₀ = 6 μM). Antiallergic and anti-inflammatory; displays antiasthmatic activity and potent antihistaminic properties in vivo.

Product Specifications for HQL 79

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for HQL 79

The following data is based on the product molecular weight 377.48.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.25 mM	10.60 mL	52.98 mL	105.97 mL
1.25 mM	2.12 mL	10.60 mL	21.19 mL
2.5 mM	1.06 mL	5.30 mL	10.60 mL
12.5 mM	0.21 mL	1.06 mL	2.12 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 3 publications citing the usage of this product.

• Matsushita Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antihistaminic effects. Jpn.J.Pharmacol. 1998 PMID: 9804057
• Mohri Prostaglandin D₂-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J.Neurosci. 2006 PMID: 16624958
• Aritake Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J.Biol.Chem. 2006 PMID: 16547010

Product Documents for HQL 79